<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724696</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1104 RYTHMIC</org_study_id>
    <nct_id>NCT02724696</nct_id>
  </id_info>
  <brief_title>French National Observatory of Patients With Thymic Epithelial Tumor</brief_title>
  <acronym>RYTHMIC</acronym>
  <official_title>French National Observatory of Patients With Thymic Epithelial Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French nationwide network for TET with the&#xD;
      objective of territorial coverage by regional expert centers and systematic discussion of&#xD;
      patients management at national tumor board.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a nationwide network for TET appointed in&#xD;
      2012 by the French National Cancer Institute. The objectives of the network are management of&#xD;
      clinical tumor boards and central pathologic review of all cases. RYTHMIC Tumor Board is&#xD;
      based on initial histopathological diagnosis.&#xD;
&#xD;
      RYTHMIC is a comprehensive tool for research:&#xD;
&#xD;
        -  to improve the management of patients&#xD;
&#xD;
        -  to monitor dedicated actions&#xD;
&#xD;
        -  to screen patients for future translational and clinical trials&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>histological type</measure>
    <time_frame>5 years</time_frame>
    <description>histological type according to the WHO classification 2004/2015</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Masaoka-Koga stage</measure>
    <time_frame>5 years</time_frame>
    <description>Masaoka-Koga stage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ITMIG/IASLC 2014/2015 stage</measure>
    <time_frame>5 years</time_frame>
    <description>ITMIG/IASLC 2014/2015 stage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questions raised at the national expert multidisciplinary tumor board</measure>
    <time_frame>5 years</time_frame>
    <description>Diagnosis/Imaging, Surgery, Chemotherapy, Radiotherapy</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3262</enrollment>
  <condition>Thymic Epithelial Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Thymic Epithelial Tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with Thymic Epithelial Tumors&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  histology other than Thymic Epithelial Tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin BESSE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Villejuif - Gustave Roussy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck Morin</last_name>
    <email>contact@ifct.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paris - Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas GIRARD, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Villejuif - Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin BESSE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Chalabreysse L, Thomas De Montpreville V, De Muret A, Hofman V, Lantuejoul S, Parrens M, Payan MJ, Rouquette I, Secq V, Girard N, Marx A, Besse B, Molina TJ. [Rythmic-pathology: the French national pathology network for thymic epithelial tumours]. Ann Pathol. 2014 Feb;34(1):87-91. doi: 10.1016/j.annpat.2014.01.010. Epub 2014 Feb 21. French.</citation>
    <PMID>24630641</PMID>
  </reference>
  <reference>
    <citation>Hadoux J, Girard N, Besse B. [Thymic epithelial neoplasms: updates on diagnosis, staging, biology and management in France]. Bull Cancer. 2012 Nov;99(11):1045-55. doi: 10.1684/bdc.2012.1659. Review. French.</citation>
    <PMID>23131309</PMID>
  </reference>
  <reference>
    <citation>Thomas de Montpréville V, Quilhot P, Chalabreysse L, De Muret A, Hofman V, Lantuéjoul S, Parrens M, Payan MJ, Rouquette I, Secq V, Girard N, Besse B, Marx A, Molina TJ. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes. Pathol Res Pract. 2015 Dec;211(12):996-1002. doi: 10.1016/j.prp.2015.10.005. Epub 2015 Oct 19.</citation>
    <PMID>26534878</PMID>
  </reference>
  <reference>
    <citation>Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Lung Cancer. 2016 Jul;97:99-104. doi: 10.1016/j.lungcan.2016.04.024. Epub 2016 May 3. Erratum in: Lung Cancer. 2016 Nov;101:146.</citation>
    <PMID>27237035</PMID>
  </reference>
  <reference>
    <citation>Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clément-Duchêne C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazières J, Besse B, Girard N. Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. J Thorac Oncol. 2018 Nov;13(11):1762-1770. doi: 10.1016/j.jtho.2018.08.005. Epub 2018 Aug 21.</citation>
    <PMID>30138763</PMID>
  </reference>
  <reference>
    <citation>Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clément-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, Girard N. Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. J Thorac Oncol. 2017 Nov;12(11):1715-1722. doi: 10.1016/j.jtho.2017.07.023. Epub 2017 Jul 31.</citation>
    <PMID>28774861</PMID>
  </reference>
  <reference>
    <citation>Drevet G, Collaud S, Tronc F, Girard N, Maury JM. Optimal management of thymic malignancies: current perspectives. Cancer Manag Res. 2019 Jul 22;11:6803-6814. doi: 10.2147/CMAR.S171683. eCollection 2019.</citation>
    <PMID>31413632</PMID>
  </reference>
  <reference>
    <citation>Remon J, Girard N, Mazieres J, Dansin E, Pichon E, Greillier L, Dubos C, Lindsay CR, Besse B. Erratum to &quot;Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network&quot; [Lung Cancer, 97 (July 2016), 99-104]. Lung Cancer. 2016 Nov;101:146. doi: 10.1016/j.lungcan.2016.09.014. Epub 2016 Oct 6.</citation>
    <PMID>27720478</PMID>
  </reference>
  <reference>
    <citation>Rouquette I, Taranchon-Clermont E, Gilhodes J, Bluthgen MV, Perallon R, Chalabreysse L, De Muret A, Hofman V, Marx A, Parrens M, Secq V, Thomas de Montpreville V, Galateau-Salle F, Brousset P, Milia J, Girard N, Besse B, Molina TJ, Mazières J. Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomark Res. 2019 Dec 4;7:28. doi: 10.1186/s40364-019-0177-8. eCollection 2019.</citation>
    <PMID>31827799</PMID>
  </reference>
  <reference>
    <citation>Girard N, Merveilleux Du Vignaux C, Molina T, Besse B, Rythmic R. [Thymic tumors]. Rev Prat. 2017 Apr;67(4):430-434. French.</citation>
    <PMID>30512890</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

